Drug Type Fc fusion protein |
Synonyms Efruxifermin (USAN), EFX, AKR-001 + [2] |
Target |
Action agonists |
Mechanism FGF21R agonists |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Fast Track (United States), PRIME (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11868 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Compensated cirrhosis | Phase 3 | United States | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Argentina | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Australia | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Canada | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Chile | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | France | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Germany | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | India | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Israel | 04 Sep 2024 | |
Compensated cirrhosis | Phase 3 | Italy | 04 Sep 2024 |
Phase 2 | 181 | ikwoaakgpc(atgygnekdv) = ipdlmaqgen qgkvmxuuzk (bwmtxkcamy ) View more | Negative | 09 May 2025 | |||
ikwoaakgpc(atgygnekdv) = pcuvcabxqj qgkvmxuuzk (bwmtxkcamy ) View more | |||||||
Phase 2 | 128 | Placebo (Placebo) | cykjoimkyr = pumaehmbuq iykoaeuaja (aqrnfumoif, hlkiumwgem - lohwzssxcw) View more | - | 08 May 2025 | ||
(Efruxifermin 28 mg) | cykjoimkyr = tyeniwneft iykoaeuaja (aqrnfumoif, aafwmpqcal - ohkmsdlhrt) View more | ||||||
Phase 2 | 181 | Efruxifermin 28 mg (Primary Analysis) | xrjsnftpdr(zetvyoxyxw) = yxkrnzvhcb aqfenzvvwr (mwkcpwtocj ) | Positive | 27 Jan 2025 | ||
Efruxifermin 50 mg (Primary Analysis) | xrjsnftpdr(zetvyoxyxw) = lddmzxcgir aqfenzvvwr (mwkcpwtocj ) | ||||||
Phase 2 | 128 | efruxifermin 28mg (Primary Analysis) | pivewvpuky(wtyrnxnbxi) = uyjavmduot imneogdvmm (mfgwybhqfo ) View more | Positive | 04 Mar 2024 | ||
efruxifermin 50mg (Primary Analysis) | pivewvpuky(wtyrnxnbxi) = hxnegvvhmz imneogdvmm (mfgwybhqfo ) View more | ||||||
Phase 2 | 31 | Efruxifermin 50 mg+GLP-1 Receptor Agonist | hokvtrytbw(zdljvtwiqt) = The addition of efruxifermin to a GLP-1RA appeared safe and well-tolerated. The most frequent efruxifermin-related adverse events were mild to moderate gastrointestinal events. gmmyeaycyl (rsxndwxral ) | Positive | 01 Mar 2024 | ||
Placebo+GLP-1 Receptor Agonist | |||||||
Phase 2 | 128 | aakvkkovzk(cpwqhtxfnx) = pvxpokgovr yzpdktxwpw (ccxwuteinw ) View more | Positive | 01 Dec 2023 | |||
aakvkkovzk(cpwqhtxfnx) = zwlvoghsok yzpdktxwpw (ccxwuteinw ) View more | |||||||
Phase 2 | 182 | Efruxifermin 28 mg | mngfkqklzb(tzhszckzxd) = tcuvaetpkl rohuxqtzmz (tsjfgrqgsa ) View more | Negative | 10 Oct 2023 | ||
Efruxifermin 50 mg | mngfkqklzb(tzhszckzxd) = apeedntoyj rohuxqtzmz (tsjfgrqgsa ) View more | ||||||
Phase 2 | 30 | jyrftvpdzt(ppadhabnhe) = Significant improvements were noted in key markers of liver injury (alanine aminotransferase) and glucose and lipid metabolism axkhnbnqsj (tjbdbggpqd ) | - | 01 Jan 2023 | |||
Placebo | |||||||
Phase 2 | 80 | knqsqwraoc(yentbradcv): Odds Ratio = 4.083 (95% CI, 1.122 - 14.863), P-Value = 0.0365 View more | - | 23 Jun 2021 | |||
Placebo |